Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits

Hims & Hers Health, Inc. (NYSE:HIMS) is currently experiencing a decline in its stock price, trading lower on Monday. The company’s stock has plummeted approximately 18% over the past month, reflecting recent challenges.

A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S (NYSE:NVO) ended its collaboration with Hims & Hers. Consequently, Hims & Hers will no longer have direct access to Wegovy, Novo Nordisk’s popular GLP-1 weight-loss drug, through the NovoCare Pharmacy.

Novo Nordisk stated in a press release that the termination was due to Hims & Hers Health’s alleged failure to adhere to laws prohibiting mass sales of compounded drugs under the false guise of “personalization” and its use of deceptive marketing practices, which Novo Nordisk claimed disregarded patient safety.

Also Read: Wegovy, Zepbound Prices Drop, But Most Patients Still Can’t Afford Long-Term Use: ‘Coverage Is Not The Same As Access,’ Says Expert

This split represents the latest challenge facing Hims & Hers, even as the company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030.

Hims & Hers Health shares are under pressure largely because the firm sells cheaper, compounded versions of popular weight-loss drugs. Regulators typically permit compounded versions of drugs to enter the market to meet demand when there’s an official shortage of the brand-name product.

However, the FDA announced earlier this year that semaglutide, the active ingredient in ...